CardioSenseSystem Compared to Philips Telemetry System Regarding Efficacy and Safety in the Monitoring of ECG

Novosense AB1 site in 1 country60 target enrollmentSeptember 2020

ConditionsCardiac Arrythmias Unstable Angina Heart Valve Disorders Disorder of Aorta

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Cardiac Arrythmias
Sponsor: Novosense AB
Enrollment: 60
Locations: 1
Primary Endpoint: Lost of monitoring data
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a prospective, controlled, comparative clinical trial of a new ECG monitoring system CardioSenseSystem prior CE marking. The aim of the study is to demonstrate that the CardioSenseSystem's cable-free ECG monitoring system (investigational device) is equivalent or better than traditional and accepted industry standard for cable-based ECG monitoring system (control device). In this study accepted industry standard is Philips Intellivue. In order to investigate this, the study will measure ECG monitoring interruptions, management time and alarm performance. The study population will consist of sixty (60) adult subjects requiring ECG and that are fulfilling the eligibility criteria for study participation. The subjects will be using both the investigational device and the control device simultaneous for measuring data loss, management time and alarm function up to 24 hours.

Detailed Description

A prospective, controlled and comparative clinical trial before CE marking of a new ECG monitoring system CardioSenseSystem. The study population will consist of sixty (60) adult subjects requiring ECG and that are fulfilling the eligibility criteria for study participation. The subjects will be monitored by both the investigational device and the control device for measuring data loss, management time and alarm function up to 24 hours. The duration of the study is estimated to 4 months. CardioSenseSystem is designed to provide wireless high-quality ECG monitoring. The system developed by Novosense AB consists of three components: the CardioPatch, the Novosense Base Station and the Back-End System. The CardioPatch is a wireless sensor capable to record and transmit ECG data. The CardioPatch send ECG data to the Novosense Base Station, which is the receiving unit. The Back-End System is used for presentation, storage and processing of ECG information. The CardioPatch sensor is applied to the body with an adhesive in the same way as a traditional ECG electrode. In contrast, the CardioPatch is a fully integrated unit containing electrodes, ECG amplifier and a radio transmitter. Novosense's wireless ECG sensors, CardioPatch, transmits the ECG signal 24 hours to the Novosense Base Station receiver.

Registry

clinicaltrials.gov

Start Date

September 2020

End Date

December 30, 2020

Last Updated

5 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Novosense AB

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male or female at least 18 years old.
•Patient hospitalized at the investigational site and in need of ECG monitoring.
•Patient with expected alarms during the 24 hours ECG monitoring.
•Patient who has been informed of the clinical trials purpose, limitations and relevance, and who has voluntarily agreed to participation in the clinical trial by signing the informed consent form.

Exclusion Criteria

•Patient with burns.
•Patient with known allergy or sensitivity to any of the compositions in CardioPatch.
•Patient with infection in the area where the electrodes are to be placed.
•Patient with fragile skin (eg after prolonged cortisone treatment).
•Patient with open sternum / sternum (eg severe heart failure postoperatively) or treatment for infection of the sternum.
•Patient with mechanical auxiliary heart or ECMO.
•Patient with implantable defibrillator.
•Severely ill patient during end of life.
•Patient participating in any other clinical trial.
•Patient where the investigator judge that participation may be risky for the patient or obstruct or interfere the implementation of the trial as approved.